Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

100.40 -1.44 (-1.41%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
What's Going On With Novo Nordisk Stock Today?
On Saturday, Novo Nordisk A/S (NYSE: NVO) releas 
Via Benzinga
Big Players' Recent Trades in NVO Options
Via Benzinga
The Magnificent Seven: 7 Stocks That Could Make It the ‘Elite Eight’
Investors curious to identify the next magnificent 7 stock should start here as the clues are fairly straightforward. 
Via InvestorPlace
Better Buy Now: Novo Nordisk vs. Eli Lilly
Both of these companies are reporting positive news for their competing weight-loss drugs, but which is the better stock to buy now? 
Via The Motley Fool
Wegovy Weight Loss Drug Cuts Heart Complication Risk, Says Trial
A clinical trial has revealed that Novo Nordisk's (NYSE: NVO) weight loss drug Wegovy significantly decreases the risk of serious heart complications. 
Via Benzinga
'Market's Had A Very Solid Winning Streak Of Late': Jim Cramer Eyes Key Retailers And CPI Data In Critical Earnings Week Ahead
CNBC market analyst Jim Cramer emphasized the importance of the upcoming week for investors,  
Via Benzinga
Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth
These stocks offer the best of both worlds. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Stocks to Buy for Retirees Looking to Beat Inflation
Retired investors looking to weather the current market with above-average returns should buy these inflation-beating retirement stocks. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. 
Via Benzinga
Widely Popular GLP-1-Based Weight Loss Drugs Reshape US Healthcare Landscape, May Help Control Addiction
Speakers at an event highlighted the impact of a new class of weight loss drugs, including substance abuse, on the U.S. 
Via Benzinga
'I Want You To Buy It, And Every Time It Dips, I Want You To Buy More': Cramer Hypes Up Auto Parts Retailer
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Broadcom Inc. (NASDAQ: AVGO) is a "buy." 
Via Benzinga
Could Novo Nordisk Stock Help You Retire a Millionaire?
The stock is up big this year, but it may surprise you just how massive your gains would need to be to reach $1 million. 
Via The Motley Fool
Novo Nordisk Seeks Obesity, Diabetes 'Bolt-On' Deals As It Beefs Up Capacity To Meet Soaring Demand
Novo Nordisk A/S (NYSE: NVO) plans to invest more than DKK 42 billion 
Via Benzinga
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
7 Biotech Stocks to Buy for Big-Time Gains
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research. 
Via InvestorPlace
The Stock-Split Stock Behind Ozempic and Wegovy Could Be Yours for Just $100
Novo Nordisk just reported financial and operating results through the first nine months of the year. One thing is clear: Demand is not an issue. 
Via The Motley Fool
Will Eli Lilly's Zepbound be the next big weight-loss drug?
Eli Lilly got regulators' OK for weight-loss drug Zepbound, which will compete with Novo Nordisk's Wegovy. Analysts see Zepbound sales as high as $37 billion 
Via MarketBeat
Look Out, Ozempic and Wegovy: Eli Lilly Has a New Weight-Loss Drug in Town
Analysts predict Lilly's tirzepatide, marketed under the Mounjaro and Zepbound brands, could achieve peak annual sales of more than $50 billion. 
Via The Motley Fool
Lilly's Strategic Branding Move For Weight Loss Drug Sets Stage For Long Term Success - Analyst
Wednesday, the FDA approved Eli Lilly And Co's (NYSE: LLY) Zepbound (tirzepatide) injection, the first and  
Via Benzinga
Exposures Product Safety
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
The company is licensing a new GLP-1 drug in the hopes of taking on Novo and Lilly. 
Via Investor's Business Daily
Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?
This competition is leading to a lot of serious innovation. 
Via The Motley Fool
Novo Nordisk Ceases Production Of One Long-Acting Insulin In US Amid Manufacturing Constraints, Competition
Novo Nordisk A/S (NYSE: NVO) has reportedly discontinued its long-acting insulin Levemir in the U.S., attributing the decision to manufacturing constraints, reduced patient access, and the availability... 
Via Benzinga
People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk Billions
Medicines can sell more when patients understand that they're priced accessibly. 
Via The Motley Fool
Weight Loss Drug Competition - FDA Approves Expanded Use Of Eli Lilly's Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk's Price
The FDA has approved  
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Novo Nordisk Stock Trounced the Market Today
A pair of pundits became notably more bullish on the company in the wake of its latest results announcement. 
Via The Motley Fool
European Pharma Rules Overhaul, Concerns Arise Over Billions In Lost Investment, Undiscovered Treatments
The European Federation of Pharmaceutical Industries and Associations (EFPIA)  
Via Benzinga
Why Novo Nordisk Stock Flopped on Friday
The news items about the company Friday were two molehills that no investor should make into mountains. 
Via The Motley Fool
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and... 
Via Benzinga
Topics Bonds Economy
Exposures Debt Markets Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.